STX17

Across TCGA pan-cancer cohorts, STX17 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated STX17 data layer compared with 24 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher STX17 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated STX17 expression acts as an unfavorable survival marker.

ESCA, LUAD, and KIRP are the cancer types where STX17 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	OS	Median	All	0.287	0.704	.010	6	view →
LUAD	DFS	Median	IV	0.342	0.893	<.001	6	view →
KIRP	OS	Median	All	0.135	0.703	.040	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

STX17–ESCA (OS)

Open the ESCA breakdown →